Viridian Therapeutics: Advances in the TED Pipeline Support Analyst Price Targets of up to $43!

Wall Street is responding with significant price target increases to the operational developments at Viridian Therapeutics. The clinical programs for the treatment of Thyroid Eye Disease (TED) are at the center of attention. Analyst Laura Chico from Wedbush estimates the stock's upside potential at over 130 percent following a renewed buy recommendation. Business Model and Strategic Orientation Viridian Therapeutics (VRDN) is a biopharmaceutical company. Its core business focuses on the development and commercialization of treatments for severe...